- Peptides are chains of amino acids joined by bonds the digestive system exists to break.
- Proteases in the stomach and small intestine act on those bonds directly.
- Even an intact chain then has to cross the intestinal barrier, which selects strongly on size.
- This is why oral bioavailability for most peptides is very low, and why route is a chemistry question rather than a preference.
Search for almost any compound in this field and the suggestions include an oral form, a nasal form and a topical form. Whether those are equivalent is a chemistry question with a fairly clear answer, and it is worth setting out because it explains a lot of what the market argues about.
This concerns material supplied for laboratory research use only, and it describes what happens to a molecule rather than what anyone should do with one.
What a peptide is, structurally
A peptide is a chain of amino acids joined by peptide bonds. That is the whole definition, and it is also the problem.
The digestive system exists to break exactly those bonds. Dietary protein is peptide chains, and digestion is the process of reducing them to amino acids for absorption. A synthetic peptide entering that system is not chemically distinguishable from any other substrate.
Two barriers, not one
The first is enzymatic. Pepsin in the stomach, then trypsin, chymotrypsin and other proteases in the small intestine, cleave peptide bonds. They are abundant, they are the point of the organ, and they do not discriminate between a peptide from food and a peptide from a vial.
The second is the intestinal barrier, and it is often the one that finishes the job. Even a chain that survives digestion must cross the epithelium to reach circulation, and that barrier selects strongly on size and on physicochemical properties. Small molecules cross readily. Peptides of the sizes discussed here mostly do not.
Together these two produce oral bioavailability figures for most peptides that are very low — commonly cited in low single-digit percentages or below, and frequently variable enough that the average is not a useful number.
Why some oral peptides do exist
Because the problem is solvable with enough engineering, and the exceptions prove the rule.
Where oral peptide products exist, they generally involve substantial formulation work: permeation enhancers that transiently open the barrier, protease inhibitors, enteric coatings that delay release, or structural modifications that resist cleavage. That machinery is the product. It is not something that happens because a peptide was pressed into a capsule.
So "the oral version of X" is a meaningful claim only if the formulation is described. Without it, the phrase usually names a route rather than a product that works by it.
Nasal and topical are different problems again
Nasal delivery bypasses the gut entirely, which removes the protease problem, and the nasal mucosa is more permeable than the intestine. It does not remove the size constraint, and the dose that reaches circulation depends heavily on formulation and on where in the cavity the spray lands.
Topical is a different question still. The skin barrier is formidable and most peptides do not cross it in quantity — which is why topical peptide work in cosmetic formulation is generally about activity at or near the surface rather than systemic delivery. GHK-Cu is the obvious example here: its long history is in topical cosmetic use, and topical and injectable preparations of it are not interchangeable propositions.
Why this matters when reading a listing
The practical point is narrow. A compound name does not specify a route, and a route does not specify a formulation. Two products can carry the same compound name and differ in everything that determines whether the molecule arrives anywhere intact.
What a laboratory report establishes is what is in the container — identity, measured content, purity where the material is a single compound. It says nothing about the route, and no report can. That distinction is covered in what a Janoshik report actually proves, and the format question specifically in pre-filled pens versus lyophilised vials.
Questions this article answers
Why can't peptides be taken orally?
Two barriers. Proteases in the stomach and small intestine cleave peptide bonds, which is what digestion is for and what a peptide is made of. Any chain that survives then has to cross the intestinal epithelium, which selects strongly on molecular size. Together these give most peptides very low oral bioavailability.
Are oral and injectable forms of the same peptide equivalent?
Not by default. The compound name is the same; what differs is how much of it survives to reach circulation, which depends entirely on formulation. An oral product that works involves substantial engineering — permeation enhancers, protease inhibitors, enteric coating or structural modification — and that engineering is the product.
What about nasal sprays?
Nasal delivery bypasses the digestive proteases and uses a more permeable mucosa, so it avoids one of the two barriers. It does not avoid the size constraint, and how much arrives depends heavily on the formulation and on where the spray lands.
Why is GHK-Cu used topically?
Its long history is in cosmetic formulation, where the activity of interest is at or near the skin surface rather than systemic. The skin barrier is formidable and most peptides do not cross it in quantity, so topical and injectable preparations are not interchangeable propositions.
Want the certificate for a real batch?
Name a compound and we'll send the manufacturer's HPLC-MS certificate for the batch you would receive — before you order, no account needed.